AngioDynamics Doubles Vascular Access Biz With Navilyst Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Deal worth $372 million makes AngioDynamics the clear number-two competitor in the global vascular access market, second only to Bard.
You may also be interested in...
AngioDynamics Gains AngioVac Clot Remover In $55 Mil. Vortex Acquisition
Deal strengthens peripheral vascular product offerings with the addition of 510(k)-cleared blood clot removal system, which AngioDynamics expects will generate $50 million in annual sales in five years.
The Evolving World Of Breast Cancer Management
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
Boston Scientific Sells Fluid Management, Venous Access Units
Private equity firm Avista Capital Partners plans to operate Boston Scientific's combined fluid management and venous access units as a stand-alone company after acquiring the businesses for $425 million on Dec. 13